Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Atogepant tablets (Qulipta) - selected U.S. label sections
Product / population
Adult QULIPTA oral migraine-prevention therapy. Preserve the episodic versus chronic indication.
Renal method
Creatinine clearance in mL/min; episodic and chronic migraine differ.
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Official
Atogepant tablets (Qulipta) - selected U.S. label sections
U.S. product labeling / DailyMed · Adult QULIPTA oral migraine-prevention therapy. Preserve the episodic versus chronic indication.
Renal method: Creatinine clearance in mL/min; episodic and chronic migraine differ. Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal regimen by migraine indication
For severe impairment (CrCl 15-29) or ESRD (below 15), the episodic-migraine dose is 10 mg once daily. On intermittent hemodialysis days, administration after dialysis is preferred. For chronic migraine, use is not recommended in severe impairment or ESRD.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.